David Semin

Amgen (United States)

Papers

1

Total Citations

52

H-Index

1

About

David Semin is a distinguished pharmaceutical scientist whose research centers on drug discovery and development, with a particular emphasis on physicochemical property optimization and high-throughput screening methodologies. His major contributions lie in advancing automated analytical techniques for determining critical drug properties, most notably aqueous solubility, which is essential for structure-property relationship (SPR) studies during lead optimization. His seminal 2005 paper, "An Automated Screening Assay for Determination of Aqueous Equilibrium Solubility Enabling SPR Study During Drug Lead Optimization," has garnered 52 citations, reflecting its lasting impact on the field. This work introduced a robust equilibrium solubility method that meets the demanding sensitivity requirements of modern drug discovery, enabling researchers to make informed decisions early in the development pipeline. Semin's innovative approach has helped bridge the gap between analytical chemistry and medicinal chemistry, providing a practical tool for evaluating drug-like properties. His research continues to influence how pharmaceutical scientists assess and optimize lead compounds, making him a notable figure in the advancement of drug lead optimization strategies.

Research Focus

Key Achievements

1
H-Index
1
Papers
52
Total Citations
52
Avg Citations/Paper
🏆 Most Cited Paper
An Automated Screening Assay for Determination of Aqueous Equilibrium Solubility Enabling SPR Study During Drug Lead Optimization
52 citations · 2005
📈 Most Prolific Year: 2005 (1 Papers)
🤝 Key Collaborators: 3
🏛 Institutions: Amgen (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago